ARCHIVES

Rev/Vel/Dex Response Rate High In Phase I/II Study

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

July 27, 2007

Contract Proposal Would Assess Outcomes Other Than Incidence, Response, Mortality

September 18, 1987

On More Victory For Sol Garb: FDA Approves THC

June 14, 1985

Shaw’s Lung Cancer, Bronchoalveolar Carcinoma, Exemplifies Elusiveness of 2015 Goal. Little Known About The Rare Disease.

February 3, 2006

NIH Alternative Medicine Office Releases RFA For Grant Awards

April 9, 1993

In Brief: FASEB Letter urges Support Of NIH, NSF; Kansas Recruits Experts From Washington State

July 30, 1993